References
- Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1–23.
- US Food and Drug Administration. FDA approves new drug to treat psoriasis [Online]. 2009 [cited 2009 Dec 7]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm183851.htm.
- Kerns MJ, Graves JE, Smith DI, Heffernan MP. Off-label uses of biologic agents in dermatology: A 2006 update. Semin Cutan Med Surg. 2006;25:226–240.
- Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151(suppl 69):3–17.
- Melnikova I. Psoriasis market. Nat Rev Drug Discov. 2009;8:767–768.
- Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009;160:1264–1272.
- Roger SD. Biosimilars: How similar or dissimilar are they? Nephrology. 2006;11:341–346.
- Nau JY. Omnitrope, first ‘biosimilar’ drug of the European Union. Rev Med Suisse. 2006;2:1206.
- Duerden M. Prescribing advice needed for new biosimilar biological drugs. Prescriber. 2007;18:1–2.
- Mehlis S, Gordon KB. Tumor necrosis factor (TNF) inhibitors. In: Wolverton SE, editor. Comprehensive dermatological drug therapy. 2nd ed. Philadelphia: Elsevier; 2007. p. 359–374.
- Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res. 2007;30:267–272.
- European Medicines Agency. Guideline on similar biological medicinal products [Online]. 2005 [cited 2009 Dec 7]. Available from: http://www.emea.eu.int/index/indexh1.htm.
- Casadevall N, Rossert J. Importance of biologic follow-ons: Experience with EPO. Best Pract Res Clin Haematol. 2005;18:381–387.